Abstract
BackgroundAdalimumab (ADA) is currently approved in the EU for the treatment of severe non-radiographic axial spondyloarthritis (nr-axSpA), in patients (pts) with an elevated CRP and/or positive MRI who have had...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have